130 related articles for article (PubMed ID: 37682780)
1. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
Bilani N; Patel R; Crowley F; Tiersten A
Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
[TBL] [Abstract][Full Text] [Related]
2. Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease.
Dosani M; Truong PT
Expert Rev Anticancer Ther; 2019 Sep; 19(9):803-810. PubMed ID: 31498712
[No Abstract] [Full Text] [Related]
3. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
4. pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era.
Dosani M; Hamilton SN; Gondara L; Speers C; Diocee RM; Nichol A; Lohrisch C; Truong P
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):805-815. PubMed ID: 35385784
[TBL] [Abstract][Full Text] [Related]
5. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
[TBL] [Abstract][Full Text] [Related]
6. pN0(i+) breast cancer: treatment patterns, locoregional recurrence, and survival outcomes.
Karam I; Lesperance MF; Berrang T; Speers C; Tyldesley S; Truong PT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):731-7. PubMed ID: 24035330
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of isolated tumor cells and micrometastases in axillary lymph nodes in breast cancer.
Madsen EV; Elias SG; van Dalen T; van Oort PM; van Gorp J; Gobardhan PD; Bongers V
Breast; 2013 Oct; 22(5):748-52. PubMed ID: 23313060
[TBL] [Abstract][Full Text] [Related]
8. Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery.
Houvenaeghel G; Cohen M; Martino M; Reyal F; Classe JM; Chauvet MP; Colombo PE; Heinemann M; Jouve E; Gimbergues P; Azuar AS; Coutant C; Gonçalves A; de Nonneville A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760536
[TBL] [Abstract][Full Text] [Related]
9. Axillary nodal disease burden is not associated with an elevated 21-gene recurrence score in post-menopausal women presenting with a clinically negative axilla.
Botty van den Bruele A; Paul MA; Thomas SM; Sammons SL; DiNome ML; Plichta JK; Record SM; Woriax H; Chiba A; Rosenberger LH; Hwang ES
Am J Surg; 2024 Jul; 233():45-51. PubMed ID: 38350748
[TBL] [Abstract][Full Text] [Related]
10. Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
Bilani N; Crowley F; Mohanna M; Itani M; Yaghi M; Saravia D; Jabbal I; Dominguez B; Liang H; Nahleh Z
Breast; 2022 Dec; 66():49-53. PubMed ID: 36137495
[TBL] [Abstract][Full Text] [Related]
11. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer.
Truong PT; Vinh-Hung V; Cserni G; Woodward WA; Tai P; Vlastos G;
Eur J Cancer; 2008 Aug; 44(12):1670-7. PubMed ID: 18595686
[TBL] [Abstract][Full Text] [Related]
12. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
Knape N; Park JH; Agala CB; Spanheimer P; Morrow M; Downs-Canner S; Baldwin XL
Ann Surg Oncol; 2023 Feb; 30(2):1042-1050. PubMed ID: 36217063
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of chemotherapy in patients with HR+/HER2-Invasive lobular breast cancer.
Yaghi M; Bilani N; Dominguez B; Zerdan MB; Li H; Saravia D; Stone E; Nahleh Z
Cancer Treat Res Commun; 2023; 34():100666. PubMed ID: 36525755
[TBL] [Abstract][Full Text] [Related]
14. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
[TBL] [Abstract][Full Text] [Related]
15. Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort
Houvenaeghel G; de Nonneville A; Cohen M; Chopin N; Coutant C; Reyal F; Mazouni C; Gimbergues P; Azuar AS; Chauvet MP; Classe JM; Daraï E; Martinez A; Rouzier R; de Lara CT; Lambaudie E; Barrou J; Goncalves A
ESMO Open; 2021 Jun; 6(3):100151. PubMed ID: 33984674
[TBL] [Abstract][Full Text] [Related]
16. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
17. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
[TBL] [Abstract][Full Text] [Related]
18. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
Colleoni M; Rotmensz N; Peruzzotti G; Maisonneuve P; Mazzarol G; Pruneri G; Luini A; Intra M; Veronesi P; Galimberti V; Torrisi R; Cardillo A; Goldhirsch A; Viale G
J Clin Oncol; 2005 Mar; 23(7):1379-89. PubMed ID: 15735114
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.
Ma X; Yang X; Yang W; Shui R
Sci Rep; 2021 May; 11(1):9534. PubMed ID: 33953240
[TBL] [Abstract][Full Text] [Related]
20. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
